Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 9Lymphoma 6Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma, Non-Hodgkin 2Waldenstrom Macroglobulinemia 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Diffuse Large B-Cell Lymphoma Refractory 1Burkitt Lymphoma 1

Interventions

tisagenlecleucel 8Cyclophosphamide 7fludarabine 5blinatumomab 5aflibercept 4ibrutinib 2epratuzumab 2Vincristine 2Radioimmunodetection 2Methotrexate 2MLN 8237 2Inotuzumab Ozogamicin 2Dexamethasone 2tocilizumab 1tafasitamab 1siltuximab 1sepantronium 1ruxolitinib 1relatlimab 1pembrolizumab 1pegaspargase 1ontuxizumab 1obinutuzumab 1loncastuximab tesirine 1forodesine 1fludarabine phosphate 1fiu protein, E coli 1exatecan 1brexucabtagene autoleucel 1asparaginase erwinia chrysanthemi recombinant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Burkitt Lymphoma × loncastuximab tesirine × Clear all
NCT02669017 2021-05-19

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

ADC Therapeutics S.A.

Phase 1 Completed
183 enrolled 38 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡